Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials.
暂无分享,去创建一个
G. Molenberghs | M. Kreuter | A. Taneja | K. Brown | V. Cottin | W. Wuyts | M. Wijsenbeek | T. Maher | P. Ford | A. Fieuw | T. Watkins | U. Costabel | S. Danoff | N. Prasad | B. van den Blink | M. J. Randall | L. Shao | R. Jenkins | E. Helmer | N. Verbruggen | B. Penninckx | S. Rocak | I. Seghers | Irene Groenveld | Garrit Jentsch | Julie Milner | Charlotte Vandenrijn
[1] Myrtle A. Davis,et al. Mechanism of hepatobiliary toxicity of the LPA1 antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: Contrasts with BMS-986234 and BMS-986278. , 2022, Toxicology and applied pharmacology.
[2] J. Goldin,et al. Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD) , 2021, BMJ Open Respiratory Research.
[3] Benjamin Weber,et al. Exposure–safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease , 2021, BMC Pulmonary Medicine.
[4] H. Adamali,et al. Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives , 2020, Clinical pharmacology : advances and applications.
[5] Dinko Žiher,et al. Benzoxaboroles—Novel Autotaxin Inhibitors , 2019, Molecules.
[6] T. McKeever,et al. The Its Not JUST Idiopathic pulmonary fibrosis Study (INJUSTIS): description of the protocol for a multicentre prospective observational cohort study identifying biomarkers of progressive fibrotic lung disease , 2019, BMJ Open Respiratory Research.
[7] H. Kwon,et al. BBT-877, a Potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis , 2019, A108. PATHOPHYSIOLOGY IN DIFFUSE PARENCHYMAL LUNG DISEASES.
[8] M. Kreuter,et al. Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2) , 2019, BMJ Open Respiratory Research.
[9] A. Taneja,et al. Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis , 2019, Clinical Pharmacokinetics.
[10] A. Prasse,et al. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry , 2019, Respiratory Research.
[11] S. Dupont,et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. , 2018, The Lancet. Respiratory medicine.
[12] L. Richeldi,et al. Idiopathic pulmonary fibrosis: pathogenesis and management , 2018, Respiratory Research.
[13] G. Criner,et al. Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions , 2017, Respirology.
[14] R. Sharif. Overview of idiopathic pulmonary fibrosis (IPF) and evidence-based guidelines. , 2017, The American journal of managed care.
[15] N. Triballeau,et al. Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fib , 2017, Journal of medicinal chemistry.
[16] S. Dupont,et al. Strong reversal of the lung fibrosis disease signature by autotaxin inhibitor GLPG1690 in a mouse model for IPF , 2016 .
[17] S. Rosselot. Idiopathic pulmonary fibrosis. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).
[18] J. Chun,et al. The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injury. , 2012, American journal of respiratory cell and molecular biology.
[19] G. Prestwich,et al. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. , 2012, American journal of respiratory cell and molecular biology.
[20] H. Collard,et al. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.
[21] J. Wain,et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak , 2008, Nature Medicine.
[22] Peter R Eastwood,et al. Six minute walk distance in healthy subjects aged 55-75 years. , 2006, Respiratory medicine.
[23] G. Molenberghs,et al. Linear Mixed Models for Longitudinal Data , 2001 .